Factors associated with spontaneous HCV clearance

Our previous work at the Zwyat Razin village cohort site had estimated HCV spontaneous clearance rate at 38.5%, with higher clearance among females compared to males (44.6% versus 33.7%, respectively; p = 0.001) (Bakr et al., Gut, 2006). Further studies in that same village showed that triglycerides levels were higher among subjects who had cleared the virus compared to those never infected, suggesting that high triglycerides might be associated with HCV clearance (Marzouk et al., Gut, 2007).The effect of lipids on HCV clearance was more pronounced among females compared to males. 


We were therefore interested to study the potential role of lipids in HCV clearance during acute infection, and to explore any potential interaction of lipids with IL28B single nucleotide polymorphisms (SNPs), which encodes type III interferon, IFN-l3 and is the best known factor associated with HCV clearance so far. A first study involving 261 patients, 130 subjects with spontaneous clearance and 131 with chronic infection, explored nine SNPs within the IL28B genomic region covering the linkage disequilibrium (LD) block known to be associated with HCV clearance in European populations. The most associated SNPs were rs12979860 (p=1.6x10-7) and the non-synonymous SNP rs8103142 (p=1.6x10-7). Interestingly, our refined analysis showed that the LD block of the IL28B SNP cluster associated with HCV clearance was shorter than that in European populations. In particular, this analysis reduced the chromosomal region in which the causal SNPs are potentially located to ~20 kilobases of the IL28B genomic region (Pedergnana et al., PLoS One, 2012). Following these results, we tested the possible association between plasma apolipoproteins levels and HCV clearance in the cohort of patients with acute hepatitis C (n=33).


Read more: Pedergnana et al., PLoS One, 2012


Note: This study has been completed and full summary of results will be available here soon.


Back to Past Research



Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union